<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of asthma during pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of asthma during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of asthma during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Schatz, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Weinberger, MD, MACP, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne E Dixon, BM, BCh</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Asthma is a common medical condition that impacts 3 to 8 percent of all pregnancies [<a href="#rid1">1-3</a>]. Pregnancy may be associated with changes in the course of asthma, and asthma may affect the outcome of pregnancy. The principles of pharmacologic therapy for asthma during pregnancy are similar to those in nonpregnant patients. When considering the use of asthma medications in a person who is pregnant or anticipates pregnancy, concerns about potential risks of asthma medication are generally outweighed by the potential adverse effects of untreated asthma.</p><p>The management of asthma in pregnancy, including the safety data for specific asthma medications, general management, and recommended pharmacotherapy for acute and chronic asthma in pregnancy, is reviewed here. An overview of asthma management and the physiology and clinical course of asthma in pregnancy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">ASSESSING DRUG SAFETY IN PREGNANCY</span><span class="headingEndMark"> — </span>Information about potential adverse effects must be interpreted with an understanding that the baseline frequency of complications in pregnancy is relatively high, even in the absence of asthma or other disorders. In the United States, major congenital anomalies occur in 2 to 4 percent of live-born infants. An overview of congenital malformations and a discussion of genetic and environmental causes are provided separately. (See  <a class="medical medical_review" href="/z/d/html/2940.html" rel="external">"Congenital anomalies: Approach to evaluation"</a>.)</p><p>There is a small but significant increase in complications of pregnancy in patients with asthma at baseline [<a href="#rid4">4</a>]. A large representative study suggests that patients with asthma, on average, have a 15 to 20 percent increased risk of perinatal mortality, preeclampsia, preterm delivery, or low birth weight infants compared with those without asthma, and that patients with more severe asthma have a 30 to 100 percent increased risk  (<a class="graphic graphic_table graphicRef59809" href="/z/d/graphic/59809.html" rel="external">table 1</a>) [<a href="#rid4">4</a>].</p><p>The US Food and Drug Administration (FDA) has discontinued use of letter categories to designate pregnancy risk and now requires information from available human and animal studies about: (1) known or potential maternal or fetal risks, (2) dose adjustments needed during pregnancy and the postpartum period, and (3) benefit/risk considerations [<a href="#rid5">5</a>].</p><p>Of note, a drug that has a strong relative contraindication to use in the first trimester may have a good safety profile when used later in pregnancy when organogenesis has been completed (eg, palate has closed).</p><p>In addition to the safety of the medication itself, a topical (inhaled) medication would appear to be preferable to a systemic one due to reduced likelihood of systemic circulation and transplacental transfer to the fetus. An older medication with a "track record" may be preferable to a newer one. Finally, absolute and relative efficacy must also be considered in the choice of a medication for use during pregnancy.</p><p class="headingAnchor" id="H2398855005"><span class="h1">MAINTAINING ASTHMA CONTROL</span><span class="headingEndMark"> — </span>Asthma may improve, worsen, or remain unchanged in severity during pregnancy [<a href="#rid6">6</a>]. The potential mechanisms involved and clinical implications of these findings are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a>.)</p><p>The two primary goals of asthma management, ie, prevention of acute exacerbations and optimization of ongoing asthma control, are unchanged in the setting of pregnancy and should serve to maximize both maternal and fetal health [<a href="#rid7">7</a>]. While use of any medication during pregnancy raises concerns about potential adverse effects on the mother or fetus, the benefit of active treatment to maintain asthma control and prevent exacerbations outweighs the potential risks of routinely used asthma medications. For example, one study of 91,000 patients with asthma during pregnancy found that those with poor asthma control had a higher incidence of recurrent (≥3) pregnancy loss compared with those whose asthma was well-controlled (odds ratio 1.6) [<a href="#rid8">8</a>].</p><p>Most routinely used controller medicines are safe during pregnancy. Potential adjustments to pharmacologic therapy are discussed further below. </p><p class="headingAnchor" id="H2904787605"><span class="h2">Adjustments to pharmacologic therapy in pregnancy</span><span class="headingEndMark"> — </span>The general principles of pharmacologic therapy for asthma during pregnancy are similar to those in nonpregnant patients and involve a step-wise approach to achieve and maintain asthma control, as recommended by national and international guidelines  (<a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">table 2</a>) [<a href="#rid9">9-11</a>]. The details of this approach are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/527.html" rel="external">"Initiating asthma therapy and monitoring in adolescents and adults"</a>.)</p><p>Current guidelines emphasize the following points [<a href="#rid9">9-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients should have access to an inhaler for quick relief of asthma symptoms. Choices include a short-acting beta-agonist (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) or a combination inhaler with <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> and a low-dose inhaled glucocorticoid (eg, formoterol-budesonide).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with mild persistent or more severe asthma, inhaled glucocorticoids reduce exacerbations during pregnancy, and cessation of inhaled glucocorticoids during pregnancy increases the risk of an exacerbation. <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">Budesonide</a> has been the preferred inhaled glucocorticoid for use during pregnancy, as more published gestational human data are available for that medication [<a href="#rid13">13,14</a>]. However, other inhaled glucocorticoids could be continued if the patient was well-controlled on one of these medications prior to pregnancy, and more recent data for <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> have been reassuring regarding the risk for low birth weight (&lt;2500 grams), small for gestational age (&lt;10<sup>th</sup> percentile for babies of same gestational age), preterm birth (&lt;37 weeks) [<a href="#rid15">15</a>], and major congenital malformations [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">Salmeterol</a> has been recommended as the inhaled long-acting beta agonist of choice in the United States due to the longer duration of clinical experience with this agent compared with <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>. However, retrospective cohort studies provide reassuring data for both salmeterol and formoterol [<a href="#rid15">15,17</a>]. Neither of these agents should be used in asthma without an inhaled glucocorticoid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although it is not the preferred therapy, a leukotriene modifier (<a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> or <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>) could be considered as an alternative for mild persistent asthma or as add-on therapy to inhaled glucocorticoids, especially for patients who have shown a uniquely favorable response to this class of agents prior to pregnancy. More pregnancy data are available for montelukast than zafirlukast. (See <a class="local">'Leukotriene modifiers'</a> below.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Safety of specific medications</span><span class="headingEndMark"> — </span>Experience with many of the medications used to treat asthma suggests minimal or no known adverse effects for their use during pregnancy [<a href="#rid3">3,11,12,18-24</a>]. Additional information and links to national databases for reproductive teratology are provided separately. (See  <a class="medical medical_review" href="/z/d/html/2940.html" rel="external">"Congenital anomalies: Approach to evaluation"</a>.)</p><p>The following sections review the safety information that is available for each of the major drug classes used in the treatment of asthma. Additional information on the fetal and neonatal risks of maternal drug ingestion during pregnancy and lactation is available from the following resources:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.perinatology.com%2Fexposures%2Fdruglist.htm&amp;token=itHzjYeOQAxPb8NSliWOVg2lTrsBY18FMbO4Cq979AeJ9kigYoL3uXUBeTnXk%2B%2FnK9mNtDqS05DhMFxVB%2FH3Eg%3D%3D&amp;TOPIC_ID=554" target="_blank">Perinatology: Drugs in pregnancy and breastfeeding</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Freprotox.org%2F&amp;token=Ryuc2NABJGKCQZO0cGQLQ%2BlIiapLy0sf7zMh%2FrkID0g%3D&amp;TOPIC_ID=554" target="_blank">Reprotox</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmothertobaby.org%2F&amp;token=cjWcuFd4xzPwN3syululi0BZIoY3uIDSoxeE%2FFYkZXAng4095mMxYKel1K7syBN0&amp;TOPIC_ID=554" target="_blank">MotherToBaby: Medications and more during pregnancy and breastfeeding</a></p><p></p><p class="headingAnchor" id="H369937555"><span class="h3">Inhaled beta-adrenergic agonists</span><span class="headingEndMark"> — </span>The majority of reports provide reassurance regarding the use of inhaled beta-agonists during pregnancy [<a href="#rid25">25-28</a>]. Clinical experience is greater with the older agents (eg, <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) than with the newer ones (eg, <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-acting beta-adrenergic agonists</strong> — The short-acting, selective beta-2 adrenergic bronchodilators (SABAs) are used to provide quick relief of asthma symptoms and appear to be relatively safe during pregnancy. However, some case-control studies have suggested a slight increase in risk of certain infant abnormalities, as noted by the following reports:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a case-control study, a small increased risk of gastroschisis was reported among infants exposed in utero to bronchodilators [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a case-control study using European registry data, gastroschisis (odds ratio [OR] 1.89, 95% CI 1.12-3.20) and cleft palate (OR 1.63, 95% CI 1.05-2.52) were associated with a greater likelihood of first trimester beta-agonist exposure [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An association with cardiac defects was noted in a cohort study that examined the effect of exposure to bronchodilator therapy during pregnancy [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A case control study reported a 30 percent increased risk (OR 1.3, 95% CI 1.1-1.5) of autism spectrum disorder in children exposed to maternal beta-2 adrenergic receptor agonist drugs during gestation [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1">One problem with assessing the consequences of bronchodilator use in pregnancy is confounding introduced by indication; SABA use is a marker for poorly-controlled asthma and more frequent exacerbations, which may independently contribute to the development of congenital anomalies [<a href="#rid33">33</a>]. Furthermore, some studies only have access to data about prescriptions filled and not the frequency of actual use [<a href="#rid30">30</a>]. Even if the statistical associations for relative risk are valid, the anomalies mentioned above are infrequent. Therefore, the absolute increase in risk is very small and, as noted earlier, less than the risk of poorly-controlled maternal asthma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-acting beta-adrenergic agents</strong> — Clinical experience with inhalation of the long-acting, selective beta-2 adrenergic bronchodilators (LABAs) during pregnancy is less extensive than with the SABAs  (<a class="graphic graphic_table graphicRef109891" href="/z/d/graphic/109891.html" rel="external">table 3</a>). <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">Salmeterol</a> is not expected to increase the risk of congenital anomalies, based on data from animal studies and limited human experience [<a href="#rid34">34</a>]. Animal studies are also reassuring for <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a>, although data from human pregnancies are limited [<a href="#rid35">35,36</a>]. A retrospective database study showed that salmeterol and formoterol do not increase the risk of delivering low birth weight, small for gestational age, or preterm infants [<a href="#rid15">15,17</a>]. Given these findings, continuation of a LABA during pregnancy is reasonable if a LABA has been needed (in combination with an inhaled glucocorticoid) to achieve asthma control before pregnancy [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent1">Human safety data for newer LABAs, such as <a class="drug drug_general" data-topicid="16792" href="/z/d/drug information/16792.html" rel="external">indacaterol</a>, <a class="drug drug_general" data-topicid="96482" href="/z/d/drug information/96482.html" rel="external">olodaterol</a>, and vilanterol are lacking. Some adverse effects were noted in animal studies of olodaterol but are not reported with indacaterol or vilanterol.</p><p></p><p class="bulletIndent1">When comparing a combination LABA plus inhaled glucocorticoid versus monotherapy with a higher dose of the inhaled glucocorticoid, the risk of congenital malformations appears similar. In a study of 1302 pregnant patients with asthma, the odds ratio for a major congenital malformation was not increased (OR 1.1, 95% CI 0.6-1.9) when a LABA plus low dose inhaled glucocorticoid was compared with a medium dose inhaled glucocorticoid or when a LABA plus medium-dose inhaled glucocorticoid was compared with a high-dose inhaled glucocorticoid (OR 1.2, 95% CI 0.5-2.7) [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">The indications for LABA therapy in asthma, the importance of combining LABA therapy with an inhaled glucocorticoid, and the controversy regarding the safety of LABA therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Combination inhaled GC/LABA'</a> and  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use"</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Oral/Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids have been used fairly extensively during pregnancy to treat asthma exacerbations and rarely for control of severe asthma. For each pregnant woman, the potential risks of gestational oral glucocorticoids must be balanced against the risks to the mother or infant of inadequately treated asthma. As the risks of severe uncontrolled asthma include maternal or fetal mortality, these risks are considered to be greater than the potential risk of systemic glucocorticoids. Thus, oral glucocorticoids should be used during pregnancy when indicated for the management of severe asthma [<a href="#rid12">12,19</a>].</p><p>Several potential areas of concern have been raised with systemic glucocorticoids: congenital malformations (primarily cleft palate), preeclampsia, gestational diabetes, low birth weight, and neonatal adrenal insufficiency. Among the studies in which systemic glucocorticoids were used for the management of asthma during pregnancy [<a href="#rid25">25,26,38-41</a>], some showed a slightly increased risk of prematurity and a slightly higher risk of low birth weight (&lt;2500 grams) [<a href="#rid25">25,26,40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital malformations</strong> – Data from animal studies in several species suggest that high dose systemic glucocorticoids may lead to cleft palate. Human studies are less concerning but a possible effect cannot be dismissed. Palatal closure is usually complete by the 12th week of pregnancy, so potential risk would be limited to administration during the first trimester. The risk of cleft lip/palate with systemic glucocorticoid use is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">"Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate", section on 'Genetic factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preterm birth and low birth weight</strong> – A large, prospective, cohort study of 2123 pregnant patients with asthma recruited from 16 centers in the United States in the period from December 1994 to February 2000 found that oral glucocorticoid use was significantly associated with preterm birth (before 37 weeks of gestation, OR 1.54, 95% CI 1.02-2.33) and low birth weight (&lt;2500 grams, OR 1.80, 95% CI 1.13-2.88) [<a href="#rid25">25</a>]. Increased prematurity and/or lower birth weights have been noted in other studies as well [<a href="#rid26">26,39,40,42-46</a>]. The authors did not evaluate the relationship between these effects and the dose or duration of therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other adverse outcomes</strong> – An increased risk of preeclampsia has been associated with oral glucocorticoid use in several studies [<a href="#rid38">38,47,48</a>]. Neonatal adrenal insufficiency following maternal administration of glucocorticoids is distinctly unusual, probably because the nonhalogenated glucocorticoids are largely metabolized to inactive metabolites by the placenta [<a href="#rid49">49</a>]. Gestational diabetes and hypertension are additional potential maternal complications of systemic glucocorticoid administration [<a href="#rid44">44</a>].</p><p></p><p>However, it remains possible that the consequences of severe uncontrolled asthma caused some or all of these reported adverse effects, given that asthma symptoms were severe enough to require oral glucocorticoids.</p><p class="headingAnchor" id="H18"><span class="h3">Inhaled glucocorticoids</span><span class="headingEndMark"> — </span>In contrast with oral/systemic glucocorticoids, the safety data on inhaled glucocorticoids are reassuring [<a href="#rid2">2,10,13,25,27,38,39,48,50-60</a>]. <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">Budesonide</a>, <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a>, and <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> are preferred among the inhaled glucocorticoids as more safety information is available for these agents [<a href="#rid3">3,10</a>]. However, if the patient’s asthma was already well-controlled on an alternate agent (eg, <a class="drug drug_general" data-topicid="8537" href="/z/d/drug information/8537.html" rel="external">ciclesonide</a>, <a class="drug drug_general" data-topicid="9663" href="/z/d/drug information/9663.html" rel="external">mometasone</a>) prior to pregnancy, there is no need to change therapy. </p><p>Examples of studies assessing the safety of inhaled glucocorticoids include the following population based studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of data on 519,242 pregnancies from three cohort studies, inhaled glucocorticoids were associated with an odds ratio for anal atresia of 3.4 (99% CI 1.15-10.04) [<a href="#rid24">24</a>]. However, no increased risk of inhaled glucocorticoids was found in relationship to 35 other specific anomalies, and chance (multiple comparisons) or residual confounding cannot be excluded as an explanation for this relationship. Moreover, anal atresia is rare and the absolute risk remains low.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of inhaled <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> during early pregnancy was assessed in a registry-based cohort study of 2014 Swedish pregnancies [<a href="#rid13">13</a>]. The rate of congenital malformations was not different from that of the general population (3.8 versus 3.5 percent). Additional data from the Swedish Medical Birth Registry reported no clinically significant effects of inhaled budesonide on fetal mortality, gestational age, or fetal growth [<a href="#rid51">51</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study using the United Kingdom's Clinical Practice Research Datalink, the risk of major congenital malformation (MCM) was assessed among 5362 pregnancies with inhaled glucocorticoid exposure during the first trimester and known fetal outcomes at one year of age [<a href="#rid16">16</a>]. Eighty-nine MCMs were identified following exposure to non-fluticasone inhaled glucocorticoids, and 42 following exposure to <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> propionate (overall 2.4 percent). When fluticasone was compared with other inhaled glucocorticoids, the adjusted odds ratio for MCM was 1.1 (95% CI 0.5-2.3), suggesting no increase in risk with fluticasone. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective database study, the odds ratios of low birth weight, preterm, or small for gestational age was not significantly different in infants from 3190 mothers exposed to <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> propionate compared with 608 mothers exposed to <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, a separate study of 13,280 pregnancies in patients with asthma confirmed that low to moderate doses of inhaled glucocorticoids were NOT associated with an increased risk of congenital malformations. However, the use of high doses (&gt;1000 mcg/day) during the first trimester was associated with a 63 percent increase in risk of all congenital malformations [<a href="#rid57">57</a>]. The strength of this observation is limited because the study was underpowered to assess the risk of specific malformations, such as cleft palate, which has been associated with maternal use of systemic glucocorticoids. In addition, the authors could not exclude the possibility that greater asthma severity contributed to the overall increased risk of malformations. Benefit-risk considerations favor the use of high dose inhaled glucocorticoids over a lower dose when needed for asthma control to avoid the use of systemic oral glucocorticoids, with the potential risks listed above. (See <a class="local">'Oral/Systemic glucocorticoids'</a> above.)</p><p></p><p>Two randomized trials support the efficacy and safety of inhaled glucocorticoids during pregnancy. One study assessed 84 pregnant patients who were managed with or without inhaled <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a> after discharge following an asthma hospitalization during pregnancy [<a href="#rid61">61</a>]. Use of this medication significantly decreased the rate of readmission for asthma (12 versus 33 percent), and no adverse events or outcomes were reported. A subsequent study compared inhaled beclomethasone to <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> in the management of moderate asthma during pregnancy [<a href="#rid54">54</a>]. Although exacerbation rates were similar in the two groups, pulmonary function was better in the beclomethasone group and fewer patients in the beclomethasone group discontinued therapy due to side effects.</p><p class="headingAnchor" id="H19"><span class="h3">Muscarinic antagonists</span><span class="headingEndMark"> — </span>Muscarinic antagonists (also known as anticholinergic agents), such as <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a>, and <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, are not generally used as a primary form of therapy for asthma. However, questions may arise about their safety during pregnancy.</p><p>The minimal chronotropic effect of inhaled <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a> in the mother suggests that the inhaled preparation should have negligible chronotropic effects on the fetus. Gestational animal studies are also reassuring for ipratropium [<a href="#rid49">49</a>]. Consequently, inhaled ipratropium, which is sometimes used for quick relief of asthma symptoms during an exacerbation, is felt to be safe for intermittent use during pregnancy [<a href="#rid12">12,62</a>].</p><p>The inhaled long-acting muscarinic antagonist (LAMA), <a class="drug drug_general" data-topicid="10300" href="/z/d/drug information/10300.html" rel="external">tiotropium</a>, is approved by the US Food and Drug Administration (FDA) for use in asthma, but is usually reserved for patients with moderate-to-severe asthma that is not controlled with a LABA-inhaled glucocorticoid combination  (<a class="graphic graphic_table graphicRef109891" href="/z/d/graphic/109891.html" rel="external">table 3</a>). The safety of inhaled tiotropium during pregnancy is uncertain as adverse effects were reported with high doses in animal studies and human fetal outcomes have not been reported [<a href="#rid10">10</a>]. Other LAMAs (eg, <a class="drug drug_general" data-topicid="86043" href="/z/d/drug information/86043.html" rel="external">aclidinium</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a>, and <a class="drug drug_general" data-topicid="95147" href="/z/d/drug information/95147.html" rel="external">umeclidinium</a>) are not approved for use in asthma, although it is reasonable to assume that they would have similar effects.</p><p class="headingAnchor" id="H12786398"><span class="h3">Leukotriene modifiers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">Montelukast</a> and <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> (leukotriene receptor antagonists) and <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a> (a 5-lipoxygenase inhibitor) are agents that affect leukotriene synthesis or action. We suggest use of montelukast or zafirlukast, in preference to zileuton, and would reserve these agents for add-on therapy to inhaled glucocorticoids, especially in patients who had a good response to this medication prior to pregnancy [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/553.html" rel="external">"Antileukotriene agents in the management of asthma"</a>.)</p><p>Accumulating evidence for <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> and <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> is reassuring, although limited.</p><p class="bulletIndent1"><span class="glyph">●</span>The first prospective, controlled study of the use of leukotriene receptor antagonists in pregnancy followed 96 women taking these medications, 122 women taking SABAs only, and 346 women without asthma. No increase in major congenital anomalies or adverse outcomes was detected in the offspring of patients receiving these medications [<a href="#rid63">63</a>]. A subsequent study with similar design described 180 montelukast-exposed pregnancies compared to 180 disease matched controls and 180 pregnancies in non-asthmatic women. In this study, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> did not appear to increase the baseline rate of major malformations, although lower birth weights were seen in both asthmatic groups [<a href="#rid64">64</a>]. Larger studies are needed to detect small increases in adverse pregnancy outcomes or rare congenital anomalies.</p><p></p><p class="bulletIndent1">A large retrospective insurance claims cohort analysis compared the incidences of selected congenital malformations in infants of mothers exposed to <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> (n = 1535), inhaled corticosteroids (n = 3918), other asthma medications (n = 8834), and controls with no asthma medications or asthma diagnoses (n = 38,828) [<a href="#rid65">65</a>]. No significant differences between groups were observed.</p><p></p><p class="bulletIndent1">No teratogenicity was observed with <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> given to rats or rabbits at doses greater than 300 times the maximum human daily oral dose on an mg/m<sup>2</sup> basis [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Animal data on <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a> have shown no teratogenicity at oral doses up to 160 times the maximum human daily oral dose on a mg/m<sup>2</sup> basis [<a href="#rid67">67</a>]. Human studies are reassuring, although the numbers of pregnancies included are small [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1">In contrast, adverse events were noted in animal reproduction studies of <a class="drug drug_general" data-topicid="10054" href="/z/d/drug information/10054.html" rel="external">zileuton</a>, and adequate studies of zileuton in pregnancy are lacking [<a href="#rid68">68</a>].</p><p></p><p class="headingAnchor" id="H3437463497"><span class="h3">Immunotherapy for allergic asthma</span><span class="headingEndMark"> — </span>The initiation of subcutaneous or sublingual allergen immunotherapy is not recommended during pregnancy due to the potential harm to the fetus should a systemic allergic reaction occur [<a href="#rid25">25,69</a>]. However, patients who are tolerating maintenance immunotherapy and deriving benefit may continue it. Immunotherapy during pregnancy is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/5552.html" rel="external">"Recognition and management of allergic disease during pregnancy", section on 'Allergen immunotherapy'</a>.)</p><p class="headingAnchor" id="H1449282207"><span class="h3">Biologics</span></p><p class="headingAnchor" id="H12786602"><span class="h4">Anti-immunoglobulin E</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a> is a humanized, recombinant IgG1, monoclonal anti-immunoglobulin E antibody approved for add-on therapy in patients with moderate to severe asthma that is inadequately controlled despite appropriate use of inhaled glucocorticoids. Studies of the safety of omalizumab in pregnancy are limited, although available data are reassuring. Immunoglobulin G molecules, such as omalizumab, are known to cross the placenta. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy"</a>.)</p><p>A prospective observational registry study reported pregnancy outcomes of 250 pregnant patients exposed to <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid70">70</a>]. The incidences of prematurity (15 percent), small for gestational age (9.7 percent), and major congenital malformations were not substantially different from outcomes reported in other studies of patients with more severe asthma. The initiation of omalizumab during pregnancy is not recommended, although if a woman becomes pregnant while receiving omalizumab, it is suggested that therapy can be continued if the benefits are estimated to outweigh the potential harms. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Safety in pregnancy and lactation'</a>.)</p><p class="headingAnchor" id="H2141530873"><span class="h4">Anti-interleukin 5</span><span class="headingEndMark"> — </span>The anti-interleukin (IL)-5 antibody preparations, <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> and <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, are approved by the FDA for add-on maintenance therapy in patients with severe eosinophilic asthma. The use of these agents in severe asthma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Anti-IL-5 therapy'</a>.)</p><p>Monoclonal antibodies, including <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> and <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a>, are likely to cross the placenta in increasing amounts as pregnancy progresses [<a href="#rid71">71,72</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of fetal harm due to <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a> was noted in monkeys at doses approximately 310 times the human dose [<a href="#rid73">73</a>]. One case report of its use during pregnancy for hypereosinophilic syndrome reported transient infant eosinopenia up to seven months of age but no other adverse effects [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of fetal harm was noted in monkeys treated with intravenous <a class="drug drug_general" data-topicid="105352" href="/z/d/drug information/105352.html" rel="external">mepolizumab</a> in doses up to 30 times the human dose [<a href="#rid75">75</a>]. There is a case report of a patient who became pregnant while on mepolizumab for severe asthma [<a href="#rid76">76</a>]. She had received two doses and discontinued it when she found out she was pregnant. She delivered a healthy child at term without congenital malformations. Information about a pregnancy exposure registry is provided in the package insert [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse events were not noted with <a class="drug drug_general" data-topicid="107564" href="/z/d/drug information/107564.html" rel="external">reslizumab</a> in animal studies (mice and rabbits), but human studies are not available [<a href="#rid71">71</a>].</p><p></p><p class="headingAnchor" id="H1848979294"><span class="h4">Anti-interleukin 4/13</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">Dupilumab</a> binds to the IL-4 receptor alpha subunit, which is also part of the IL-13 receptor. It is approved in the United States for the treatment of moderate to severe eosinophilic asthma or oral corticosteroid-dependent asthma. No adverse developmental effects were observed in offspring born to pregnant monkeys after subcutaneous dupilumab at doses up to ten times the maximum recommended human dose [<a href="#rid77">77</a>]. There are no reports regarding its use for asthma during pregnancy, but there are reports of seven patients who received dupilumab during pregnancy for atopic dermatitis (n = 6) or pemphigoid gestationis (n = 1) [<a href="#rid78">78</a>]. All seven pregnancies led to live births with one premature birth and one low birth weight infant.</p><p class="headingAnchor" id="H3078390329"><span class="h4">Anti-thymic stromal lymphopoietin (TSLP)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="134676" href="/z/d/drug information/134676.html" rel="external">Tezepelumab</a> inhibits the action of TSLP, an epithelial cell-derived cytokine involved in the pathogenesis of asthma. There was no evidence of fetal harm following intravenous administration throughout pregnancy in monkeys [<a href="#rid79">79</a>], but there are no human data available.</p><p class="headingAnchor" id="H20"><span class="h3">Rarely used medications</span><span class="headingEndMark"> — </span>Methylxanthines and cromoglycates are rarely used in the management of asthma due to the availability of alternative agents with greater effectiveness and ease of use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methylxanthines</strong> – The clinical use of methylxanthines (<a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>, <a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">aminophylline</a>) during pregnancy is limited because of the potential for altered metabolism during pregnancy, the need for drug level monitoring, and the potential for fetal tachycardia and irritability at the time of delivery. Moreover, inhaled glucocorticoids have been shown to be more effective than theophylline for persistent asthma in non-pregnant patients and at least as effective as theophylline with fewer side effects during pregnancy [<a href="#rid12">12,54</a>]. Extensive clinical experience suggests that theophylline does not increase the risk of fetal anomalies [<a href="#rid3">3,21</a>].</p><p></p><p class="bulletIndent1">Methylxanthine binding to albumin and hepatic clearance are altered during pregnancy, necessitating careful assessment of serum levels and adjustments to dosing over the course of pregnancy. (See  <a class="medical medical_review" href="/z/d/html/560.html" rel="external">"Theophylline use in asthma"</a>.)</p><p></p><p class="bulletIndent1">Like the beta-2 adrenergic agonists, <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> can inhibit uterine muscle contraction in vitro, but this effect has not been shown to be clinically important. Methylxanthines are transferred across the placenta, leading to theophylline concentrations in neonatal and cord blood that are similar to those in maternal blood [<a href="#rid80">80</a>]. Transient tachycardia and irritability have been reported in some neonates of mothers receiving methylxanthines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cromoglycates</strong> – The availability of <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> sodium and <a class="drug drug_general" data-topicid="9987" href="/z/d/drug information/9987.html" rel="external">nedocromil</a> is highly limited. These agents are no longer recommended for asthma by international guidelines [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1">Animal and limited human data on use during pregnancy (n = 318) have not demonstrated an increase in fetal malformations or other adverse effects with <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> sodium [<a href="#rid38">38,62</a>]. The one study that reported an increase in musculoskeletal abnormalities with maternal use of chromones had a very small number of exposures (n = 5), limiting the strength of the observation [<a href="#rid18">18</a>]. </p><p></p><p class="headingAnchor" id="H907812561"><span class="h2">Nonpharmacologic treatments</span><span class="headingEndMark"> — </span>The main nonpharmacologic interventions to maintain asthma control during pregnancy are patient education, avoidance of irritants (eg, cigarette smoke) and control of allergenic triggers of asthma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient education</strong> – The principles of patient education are generally similar for the pregnant and nonpregnant patient with asthma. Important issues include early recognition of signs and symptoms of an asthma exacerbation, avoidance of precipitating factors, correct use of medications, and development of a treatment plan for acute exacerbations. (See  <a class="medical medical_review" href="/z/d/html/566.html" rel="external">"Asthma education and self-management"</a> and  <a class="medical medical_patient" href="/z/d/html/6719.html" rel="external">"Patient education: Asthma and pregnancy (Beyond the Basics)"</a>.)</p><p></p><p class="bulletIndent1">The primary issues that are specific for pregnancy are education about the interrelationships between asthma and pregnancy and the safety of asthma medications during pregnancy. The clinician should clearly explain that it is safer for pregnant patients with asthma to take asthma medications than to have ongoing symptoms or exacerbations of asthma [<a href="#rid11">11,33,83</a>]. Patients should be reassured that safe and adequate asthma treatment is possible during pregnancy and that good asthma control can help to minimize the risk of complications [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking cessation</strong> – It is critical for the pregnant asthmatic mother to discontinue smoking during pregnancy [<a href="#rid84">84</a>]. First, smoking may predispose the patient to asthma exacerbations, bronchitis or sinusitis, and therefore necessitate an increased need for medication [<a href="#rid85">85</a>]. Second, cigarette smoking is associated with numerous adverse pregnancy outcomes, including spontaneous pregnancy loss, placental abruption, preterm premature rupture of membranes (PPROM), placenta previa, preterm labor and delivery, low birth weight, and ectopic pregnancy. The risks associated with maternal smoking during pregnancy and methods to enable smoking cessation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate", section on 'Adverse outcomes'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Control of environmental triggers</strong> – Control of environmental triggers is a particularly important component of the management of asthma during pregnancy as it helps to reduce the need for pharmacologic intervention. This includes avoiding exposure to allergens and to nonspecific airway irritants, such as tobacco smoke, dust, and environmental pollutants. Particular allergens of concern are dander from pets and antigens from household dust mites. (See  <a class="medical medical_review" href="/z/d/html/530.html" rel="external">"Allergen avoidance in the treatment of asthma and allergic rhinitis"</a> and  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a>.)</p><p></p><p class="headingAnchor" id="H3735883015"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Careful follow-up by clinicians experienced in managing asthma is essential. The optimal frequency of asthma evaluations is not known; generally, the frequency is determined based on the prepregnancy degree of asthma control. In an observational study, visits every four weeks improved adherence to controller medication and asthma control [<a href="#rid86">86</a>]. All pregnant patients should have ready access to their clinician should their symptoms change or increase. It is also important that effective communication exists among the clinician managing the asthma, the patient, and the obstetrician.</p><p>Diminished pulmonary function during pregnancy is associated with adverse perinatal outcomes [<a href="#rid83">83,87</a>]; it is therefore important to monitor pulmonary function in patients with asthma. Normal pregnancy-related changes in pulmonary function are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4788.html" rel="external">"Maternal adaptations to pregnancy: Dyspnea and other physiologic respiratory changes", section on 'Physiologic pulmonary changes in pregnancy'</a>.)</p><p>Although monitoring pulmonary function using spirometry can be useful, measurement of peak expiratory flow (PEF) or forced expiratory volume in one second (FEV<sub>1</sub>) using a portable device offers the advantages of less expense and greater ease of serial measurements at home. The frequency of measurement should be individualized; patients with more severe asthma may need to measure their PEF twice a day: upon awakening and approximately 12 hours later. Measurement of PEF during times of worsening symptoms can also provide a real-time assessment of the patient’s condition and guide the need for more intensive therapy. (See  <a class="medical medical_review" href="/z/d/html/568.html" rel="external">"Peak expiratory flow monitoring in asthma"</a>.)</p><p>An additional issue for pregnant patients with asthma is the difficulty differentiating symptoms due to an exacerbation of asthma from the normal sensation of dyspnea experienced during pregnancy. The presence of cough and wheezing suggests asthma. Objective information can also be obtained by measurement of the PEF or FEV<sub>1</sub>; reductions in either suggest an asthma exacerbation. (See  <a class="medical medical_review" href="/z/d/html/4788.html" rel="external">"Maternal adaptations to pregnancy: Dyspnea and other physiologic respiratory changes"</a> and  <a class="medical medical_review" href="/z/d/html/543.html" rel="external">"Asthma in adolescents and adults: Evaluation and diagnosis", section on 'Pulmonary function testing'</a>.)</p><p>A parallel group, randomized trial in 220 pregnant patients with asthma demonstrated reduced exacerbations in patients managed based on an algorithm that included fractional exhaled nitric oxide (FE<sub>NO</sub>) and the Asthma Control Questionnaire (ACQ) compared with an algorithm based on the ACQ alone [<a href="#rid88">88</a>]. Further evaluation of FE<sub>NO</sub>-guided management in other populations of pregnant patients with asthma is needed. (See  <a class="medical medical_review" href="/z/d/html/542.html" rel="external">"Exhaled nitric oxide analysis and applications", section on 'Clinical use of FENO in asthma'</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">ACUTE EXACERBATIONS</span><span class="headingEndMark"> — </span>Acute asthma exacerbations are common during pregnancy and increase the risk of preeclampsia, gestational diabetes, placental abruption and placenta previa [<a href="#rid46">46,89,90</a>]. The recommended pharmacotherapy of acute asthma during pregnancy does not differ substantially from the management in non-pregnant patients  (<a class="graphic graphic_table graphicRef67529" href="/z/d/graphic/67529.html" rel="external">table 4</a>) [<a href="#rid91">91</a>]. Intensive monitoring of both mother and fetus is essential. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p class="headingAnchor" id="H1375655453"><span class="h2">Maternal and fetal monitoring</span><span class="headingEndMark"> — </span>For acute asthma exacerbations that require emergency department management or hospitalization, fetal monitoring may be indicated in addition to routine monitoring for asthma [<a href="#rid92">92</a>]. Early consultation with the obstetrics service for co-management is appropriate.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal monitoring</strong> – Continuous measurement of oxygen saturation by pulse oximetry (SpO<sub>2</sub>) is prudent, aiming for a SpO<sub>2</sub> ≥95 percent. Measurement of expiratory airflow with a peak flow meter (or spirometer) is the best method for objective assessment of the severity of an asthma attack. Peak flow measurements can also be used to monitor a patient's response to treatment and as a predictive marker for the possibility of hypercapnia. Normal values for peak expiratory flow are not significantly altered by pregnancy.</p><p></p><p class="bulletIndent1">The changes in blood gases that occur secondary to acute asthma during pregnancy are superimposed on the "normal" respiratory alkalosis of pregnancy. Thus, an arterial carbon dioxide tension (PaCO<sub>2</sub>) &gt;35 mmHg or an arterial oxygen tension (PaO<sub>2</sub>) &lt;70 mmHg associated with acute asthma can represent more severe compromise during pregnancy than in the nongravid state. (See  <a class="medical medical_review" href="/z/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a>.)</p><p></p><p class="bulletIndent1">A chest radiograph is not indicated for the majority of asthma exacerbations and is reserved for patients with suspected pneumonia, pneumothorax, or impending or actual respiratory failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fetal monitoring</strong> – Fetal heart rate monitoring is the best available method for determining whether the fetus is adequately oxygenated. After 23 to 24 weeks of gestation, noninvasive fetal heart rate monitoring is appropriate during asthma exacerbations requiring emergency department treatment or hospitalization. The fetal heart rate tracing should be evaluated by a clinician experienced in fetal heart rate assessment. (See  <a class="medical medical_review" href="/z/d/html/409.html" rel="external">"Nonstress test and contraction stress test"</a>.)</p><p></p><p class="headingAnchor" id="H272296412"><span class="h2">Supportive care</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maternal positioning</strong> – In general, pregnant patients with acute asthma should rest in a seated or lateral position, rather than supine, particularly in the third trimester, to avoid aortocaval compression by the gravid uterus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydration</strong> – Intravenous fluids are not necessary unless the patient is unable to maintain oral hydration.</p><p></p><p class="headingAnchor" id="H2372798532"><span class="h2">Supplemental oxygen</span><span class="headingEndMark"> — </span>Supplemental oxygen (initially 3 to 4 L/min by nasal cannula) should be administered, adjusting the fraction of inspired oxygen (FiO<sub>2</sub>) to maintain a PaO<sub>2</sub> of at least 70 mmHg and/or oxygen saturation by pulse oximetry of 95 percent or greater [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H30"><span class="h2">Medications</span><span class="headingEndMark"> — </span>The recommended agents for management of acute asthma exacerbations in pregnant patients are the same as for asthma exacerbations in nonpregnant adults and adolescents. These agents include inhaled short-acting beta agonists, inhaled <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, oral or intravenous glucocorticoids, and, if appropriate, intravenous <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a>  (<a class="graphic graphic_table graphicRef67529" href="/z/d/graphic/67529.html" rel="external">table 4</a>). (See <a class="local">'Safety of specific medications'</a> above and  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a> and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management"</a>.)</p><p>Additional points regarding pharmacotherapy include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic glucocorticoids</strong> – The indications for systemic glucocorticoids are the same for pregnant patients experiencing an asthma exacerbation as for nonpregnant patients. Patients should be reassured that the benefits of oral glucocorticoids in preventing exacerbations from becoming life-threatening asthma outweigh any risk to the mother or fetus [<a href="#rid11">11,93</a>]. Doses of systemic glucocorticoids for acute asthma exacerbations in pregnancy are not different than those recommended for non-pregnant patients, as glucocorticoid bioavailability does not appear to be affected by pregnancy [<a href="#rid94">94</a>]. (See <a class="local">'Oral/Systemic glucocorticoids'</a> above and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Systemic glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">Ipratropium</a> – The muscarinic antagonist, ipratropium, is often used to treat severe acute asthma exacerbations. As noted above, inhaled ipratropium is felt to be safe during pregnancy [<a href="#rid12">12,62</a>]. (See <a class="local">'Muscarinic antagonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a> – Intravenous magnesium sulfate may be beneficial in acute severe asthma as an adjunct to inhaled beta agonists and intravenous glucocorticoids [<a href="#rid94">94</a>]. Magnesium sulfate is among the most extensively studied medications in pregnancy. It is routinely given to prevent eclamptic seizures and appears to have neuroprotective effects for the neonate if administered prior to preterm birth. It also may decrease the frequency of uterine contractions. (See  <a class="medical medical_review" href="/z/d/html/4481.html" rel="external">"Neuroprotective effects of in utero exposure to magnesium sulfate"</a> and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management", section on 'Magnesium sulfate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral beta-agonists</strong> – Parenteral beta-agonists are rarely needed for asthma exacerbations. Due to theoretic concerns that the alpha–adrenergic effects of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> might cause vasoconstriction in the uteroplacental circulation, the Working Group on Pregnancy and Asthma recommended that epinephrine generally be avoided during pregnancy except in the setting of anaphylaxis [<a href="#rid12">12</a>]. For the rare patient who requires use of a systemic beta-agonist to treat asthma, subcutaneous administration of <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a> is a reasonable choice  (<a class="graphic graphic_table graphicRef67529" href="/z/d/graphic/67529.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">The safety of <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a> is suggested by its use as a tocolytic agent (ie, as inhibitors of uterine contraction) in the setting of premature labor. When given for tocolysis, the major maternal adverse effects are hyperglycemia, hypokalemia, and, less commonly, noncardiogenic pulmonary edema. Prenatally exposed neonates have been found to have tachycardia, hypoglycemia, and tremor. However, these effects in the neonate are treatable, reversible, and not considered a contraindication to use. (See  <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">"Inhibition of acute preterm labor", section on 'Beta-agonists (eg, terbutaline)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><a class="drug drug_general" data-topicid="8620" href="/z/d/drug information/8620.html" rel="external">aminophylline</a><strong>/</strong><a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> is NOT generally recommended for use in the emergency management of acute gestational asthma because aminophylline/theophylline provides no additional benefit to optimal inhaled beta agonist and intravenous glucocorticoid therapy [<a href="#rid12">12,61</a>]. In addition, when used in combination with intensive inhaled beta-agonist therapy, intravenous aminophylline causes increased adverse side effects [<a href="#rid12">12</a>].</p><p></p><p>More detailed discussions of the treatment of acute exacerbations of asthma and acute respiratory failure due to asthma exacerbation are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1599.html" rel="external">"Acute respiratory failure during pregnancy and the peripartum period", section on 'Asthma exacerbation'</a> and  <a class="medical medical_review" href="/z/d/html/570.html" rel="external">"Invasive mechanical ventilation in adults with acute exacerbations of asthma"</a> and  <a class="medical medical_review" href="/z/d/html/119093.html" rel="external">"Acute exacerbations of asthma in adults: Emergency department and inpatient management"</a>.)</p><p class="headingAnchor" id="H31"><span class="h2">Respiratory infections</span><span class="headingEndMark"> — </span>Most respiratory infections that trigger an exacerbation of asthma are viral rather than bacterial and do not require antibiotic therapy [<a href="#rid9">9</a>]. However, testing for and treatment of influenza and COVID-19 may be appropriate, depending on the time of year and symptom pattern. The treatment of respiratory infections during pregnancy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4793.html" rel="external">"Approach to the pregnant patient with a respiratory infection"</a>.)</p><p class="headingAnchor" id="H1941559749"><span class="h1">PREVENTION OF ASTHMA/WHEEZE IN NEXT GENERATION</span><span class="headingEndMark"> — </span>Parents with asthma are more likely to have children with asthma due to a complex mixture of genetic and environmental contributors. Among risk factors for asthma or early childhood wheeze, a few are potentially modifiable, such as maternal cigarette smoking during pregnancy, poorly-controlled maternal asthma, and maternal vitamin D insufficiency. To mitigate these risk factors, we advise mothers with asthma to avoid cigarette smoking to protect their own and their child’s respiratory health (see <a class="local">'Nonpharmacologic treatments'</a> above); we aim for optimal asthma control, stepping asthma therapy up or down, as needed (see <a class="local">'Maintaining asthma control'</a> above); and we suggest maternal vitamin D supplementation based on the evidence described below (see <a class="local">'High-dose vitamin D'</a> below). Numerous other risk factors for asthma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/572.html" rel="external">"Risk factors for asthma"</a>.)</p><p class="headingAnchor" id="H357010903"><span class="h2">High-dose vitamin D</span><span class="headingEndMark"> — </span>Accumulating evidence suggests that high-dose maternal vitamin D supplementation during pregnancy might reduce the risk of early life asthma/wheeze in the offspring [<a href="#rid95">95,96</a>]. For pregnant patients whose children are at high risk of asthma (eg, one or both parents have asthma), we suggest high-dose vitamin D supplementation (eg, 2000 to 4000 IU/day, preferably D<sub>3</sub>) in addition to the Recommended Dietary Allowance (RDA) of vitamin D 600 IU/day (in prenatal vitamins). Serum 25-hydroxyvitamin D levels may be helpful to guide high-dose supplementation. (See  <a class="medical medical_review" href="/z/d/html/572.html" rel="external">"Risk factors for asthma", section on 'Vitamin D'</a> and  <a class="medical medical_review" href="/z/d/html/572.html" rel="external">"Risk factors for asthma", section on 'Vitamin D in infancy'</a> and  <a class="medical medical_review" href="/z/d/html/453.html" rel="external">"Nutrition in pregnancy: Dietary requirements and supplements", section on 'Calcium and vitamin D'</a>.)</p><p>Evidence in favor of high dose vitamin D supplementation to reduce the risk of wheeze or asthma (up to age three) comes from a meta-analysis of two randomized trials, the Vitamin D Antenatal Asthma Reduction Trial (VDAART; 4400 IU versus 400 IU) and the Copenhagen Prospective Studies on Asthma in Childhood trial (COPSAC2010; 2800 IU versus 400 IU), which are described separately (see  <a class="medical medical_review" href="/z/d/html/572.html" rel="external">"Risk factors for asthma", section on 'Vitamin D'</a>) [<a href="#rid95">95,97,98</a>].</p><p>Briefly, the meta-analysis found that maternal vitamin D intake was protective for the occurrence of wheeze or asthma in the offspring up to age three (adjusted OR 0.74, 95% CI, 0.57-0.96) [<a href="#rid95">95</a>]. An important point is that these trials only performed vitamin D supplementation during the prenatal phase, and analysis of the participants at age six suggests a loss of benefit [<a href="#rid99">99,100</a>]. No supplementation was undertaken after birth, and it remains to be seen whether additional post-natal supplementation will sustain the protective effect seen in early life. (See  <a class="medical medical_review" href="/z/d/html/572.html" rel="external">"Risk factors for asthma", section on 'Vitamin D in infancy'</a>.)</p><p>High-dose vitamin D supplementation during pregnancy appears safe; it is associated with a lower risk of small-for-gestational-age and no increase in risk of fetal or neonatal mortality or congenital abnormality [<a href="#rid101">101</a>]. In addition, no adverse events attributable to vitamin D intake were reported in the VDAART and COPSAC2010 trials [<a href="#rid97">97,98</a>].</p><p class="headingAnchor" id="H32"><span class="h1">PERIPARTUM CARE</span><span class="headingEndMark"> — </span>A few issues are relevant to the peripartum management of the asthmatic patient and her baby [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">Oxytocin</a> is the drug of choice for induction of labor and control of postpartum hemorrhage [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">"Postpartum hemorrhage: Management approaches requiring laparotomy", section on 'Evaluation of the abdomen at laparotomy'</a> and  <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer additional uterotonic medications'</a> and  <a class="medical medical_review" href="/z/d/html/4476.html" rel="external">"Induction of labor with oxytocin"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analogs of prostaglandin F2-alpha (eg, carboprost) can cause bronchoconstriction [<a href="#rid103">103,104</a>] and should <strong>not</strong> be used for termination of pregnancy, cervical ripening, induction of labor, or control of uterine hemorrhage [<a href="#rid105">105</a>]. (See  <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer additional uterotonic medications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prostaglandin E2 (<a class="drug drug_general" data-topicid="9368" href="/z/d/drug information/9368.html" rel="external">dinoprostone</a>, in gel or suppository form) and prostaglandin E1 (<a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>) are considered safer analogs, if prostaglandin treatment is required, due to their bronchodilatory effects [<a href="#rid106">106</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For peripartum pain control, <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">morphine</a> and <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a> should be avoided, if possible, since they can induce histamine release, especially from skin mast cells; however, evidence of acute bronchoconstriction caused by these agents is lacking. <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">Butorphanol</a> or <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> may be appropriate alternatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epidural anesthesia is preferred for the asthmatic patient who opts for pain control during labor because it reduces oxygen consumption and minute ventilation in the first and second stages of labor and usually can provide adequate anesthesia if cesarean delivery becomes necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If general anesthesia is required, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> and halogenated anesthetics are preferred, because they may have a bronchodilatory effect. (See  <a class="medical medical_review" href="/z/d/html/94358.html" rel="external">"Anesthesia for adult patients with asthma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Isolated case reports have described bronchoconstriction following use of ergot derivatives (eg, <a class="drug drug_general" data-topicid="9415" href="/z/d/drug information/9415.html" rel="external">ergonovine</a>) in the peripartum care of patients with asthma [<a href="#rid12">12</a>]; this may be an idiosyncratic reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If high doses of SABA have been given during labor and delivery, blood glucose levels should be monitored in the baby (especially if preterm) for the first 24 hours.</p><p></p><p class="headingAnchor" id="H3436848636"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112325.html" rel="external">"Society guideline links: Asthma in adolescents and adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/121862.html" rel="external">"Society guideline links: Respiratory disease in pregnancy"</a>.)</p><p class="headingAnchor" id="H102657112"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16119.html" rel="external">"Patient education: Asthma and pregnancy (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/371.html" rel="external">"Patient education: Asthma treatment in adolescents and adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/6719.html" rel="external">"Patient education: Asthma and pregnancy (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/373.html" rel="external">"Patient education: Trigger avoidance in asthma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/366.html" rel="external">"Patient education: How to use a peak flow meter (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/369.html" rel="external">"Patient education: Inhaler techniques in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H102656489"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles of asthma control during pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asthma may improve, worsen, or remain unchanged in severity during pregnancy. The potential mechanisms involved and clinical implications of these findings are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/555.html" rel="external">"Asthma in pregnancy: Clinical course and physiologic changes"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The two primary goals of asthma therapy during pregnancy are preventing acute exacerbations and minimizing impairment (as reflected by symptoms, interference with sleep or activity, and reduced pulmonary function).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The four important components of effective asthma therapy during pregnancy are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Objective monitoring of maternal lung function and fetal well-being as a guide to therapy (see  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Follow-up monitoring'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Proper control of environmental and other triggers for asthma (eg, cigarette smoking, animal allergen exposure) (see <a class="local">'Nonpharmacologic treatments'</a> above and  <a class="medical medical_review" href="/z/d/html/562.html" rel="external">"Trigger control to enhance asthma management"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patient education (see  <a class="medical medical_review" href="/z/d/html/566.html" rel="external">"Asthma education and self-management"</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pharmacologic therapy (see <a class="local">'Adjustments to pharmacologic therapy in pregnancy'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic control of asthma during pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Studies are reassuring regarding the rarity of adverse effects on human pregnancy outcomes with <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a> and inhaled glucocorticoids (especially <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a>, and <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a>). Reassuring animal studies have been reported with <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, <a class="drug drug_general" data-topicid="9987" href="/z/d/drug information/9987.html" rel="external">nedocromil</a>, <a class="drug drug_general" data-topicid="10052" href="/z/d/drug information/10052.html" rel="external">zafirlukast</a>, <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, and <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, but published experience in human pregnancy with these agents is more limited. Some reassuring human gestational data exist for <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> and <a class="drug drug_general" data-topicid="9875" href="/z/d/drug information/9875.html" rel="external">salmeterol</a>. (See <a class="local">'Safety of specific medications'</a> above and  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy", section on 'Safety in pregnancy and lactation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The general principles of pharmacologic therapy for asthma during pregnancy are similar to those in nonpregnant patients and involve a step-wise approach, as recommended by national and international guidelines  (<a class="graphic graphic_table graphicRef127798" href="/z/d/graphic/127798.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef53233" href="/z/d/graphic/53233.html" rel="external">table 5</a>). (See <a class="local">'Maintaining asthma control'</a> above and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We do not initiate allergen immunotherapy during pregnancy due to risk of fetal harm from systemic allergic reactions. However, allergen immunotherapy can be continued during pregnancy in patients already receiving it who appear to be deriving benefit, who are not prone to systemic reactions, and who are receiving a maintenance concentration. (See <a class="local">'Immunotherapy for allergic asthma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A few medication preferences have been identified for asthma management during pregnancy based on greater experience in treating patients with these medications (see <a class="local">'Adjustments to pharmacologic therapy in pregnancy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For relief of acute asthma symptoms, we suggest using the short-acting beta-agonist (SABA) <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, rather than other SABAs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). An alternative recommended in current international guidelines is to use a combination inhaler with <a class="drug drug_general" data-topicid="8946" href="/z/d/drug information/8946.html" rel="external">formoterol</a> and a low-dose inhaled glucocorticoid (eg, formoterol-budesonide) for quick relief (and maintenance if maintenance therapy is indicated), although more safety data exist for albuterol than for formoterol. This approach has not been specifically studied in pregnancy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who require a long-term controller for asthma, we suggest using <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a>, <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">beclomethasone</a>, or <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> as the preferred inhaled glucocorticoid (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, other inhaled glucocorticoids can be continued if the patient was well-controlled on one of these medications prior to pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of asthma exacerbations during pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The management of acute asthma exacerbations during pregnancy does not differ substantially from that of nonpregnant patients and includes treatment with inhaled short-acting beta-agonist <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>, inhaled <a class="drug drug_general" data-topicid="8570" href="/z/d/drug information/8570.html" rel="external">ipratropium</a>, oral or intravenous glucocorticoids, and, if necessary, intravenous <a class="drug drug_general" data-topicid="9585" href="/z/d/drug information/9585.html" rel="external">magnesium sulfate</a>  (<a class="graphic graphic_table graphicRef67529" href="/z/d/graphic/67529.html" rel="external">table 4</a>). Intensive monitoring of both mother and fetus is essential. (See <a class="local">'Acute exacerbations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Potential areas of concern have been raised with the use of systemic glucocorticoids, including slightly increased risks of congenital malformations (primarily cleft palate), preeclampsia, low birth weight, and neonatal adrenal insufficiency. However, these potential risks of systemic glucocorticoids are small compared with the substantial risk to the mother and fetus of severe, uncontrolled asthma. Dosages of glucocorticoids for treatment of acute asthma exacerbations in pregnancy are not different than those for non-pregnant patients. (See <a class="local">'Oral/Systemic glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the rare patient who requires use of a systemic beta-agonist to treat asthma, we suggest subcutaneous administration of <a class="drug drug_general" data-topicid="9977" href="/z/d/drug information/9977.html" rel="external">terbutaline</a> rather than <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>  (<a class="graphic graphic_table graphicRef67529" href="/z/d/graphic/67529.html" rel="external">table 4</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is based on a concern about potential uterine artery vasoconstriction with systemic administration of epinephrine  (<a class="graphic graphic_table graphicRef67529" href="/z/d/graphic/67529.html" rel="external">table 4</a>). (See <a class="local">'Medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma prevention in offspring</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnancies where the resulting child has at least one parent with asthma, we suggest maternal supplementation with high-dose vitamin D (eg, 2000 to 4000 IU/day, preferably vitamin D<sub>3</sub>) to reduce early childhood respiratory symptoms (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Serum 25-hydroxyvitamin D levels may be helpful to guide supplementation. (See <a class="local">'High-dose vitamin D'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripartum care of patients with asthma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pharmacologic induction of labor and control of postpartum hemorrhage in patients with asthma, <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">oxytocin</a> appears to be safe in pregnancy. (See <a class="local">'Peripartum care'</a> above and  <a class="medical medical_review" href="/z/d/html/4476.html" rel="external">"Induction of labor with oxytocin", section on 'Oxytocin administration'</a> and  <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">"Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer additional uterotonic medications'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with asthma who require prostaglandin treatment for termination of pregnancy, cervical ripening, induction of labor, or control of uterine hemorrhage, we recommend using prostaglandin E1 or E2, rather than analogs of prostaglandin F2-alpha (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). This recommendation is based on the risk of bronchoconstriction associated with the latter agent. (See <a class="local">'Peripartum care'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol 2003; 13:317.</a></li><li><a class="nounderline abstract_t">Van Zutphen AR, Bell EM, Browne ML, et al. Maternal asthma medication use during pregnancy and risk of congenital heart defects. Birth Defects Res A Clin Mol Teratol 2015; 103:951.</a></li><li><a class="nounderline abstract_t">Namazy J, Schatz M. The Treatment of Allergic Respiratory Disease During Pregnancy. J Investig Allergol Clin Immunol 2016; 26:1.</a></li><li><a class="nounderline abstract_t">Källén B, Rydhstroem H, Aberg A. Asthma during pregnancy--a population based study. Eur J Epidemiol 2000; 16:167.</a></li><li class="breakAll">FDA Announcement: https://www.federalregister.gov/articles/2014/12/04/2014-28241/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on June 10, 2016).</li><li><a class="nounderline abstract_t">Gluck JC, Gluck PA. The effect of pregnancy on the course of asthma. Immunol Allergy Clin North Am 2006; 26:63.</a></li><li><a class="nounderline abstract_t">Namazy JA, Schatz M. Update in the treatment of asthma during pregnancy. Clin Rev Allergy Immunol 2004; 26:139.</a></li><li><a class="nounderline abstract_t">Tidemandsen C, Egerup P, Ulrik CS, et al. Asthma Is Associated With Pregnancy Loss and Recurrent Pregnancy Loss: A Nationwide Cohort Study. J Allergy Clin Immunol Pract 2022; 10:2326.</a></li><li class="breakAll">National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma 2007 (EPR-3). 2012. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on August 31, 2021).</li><li><a class="nounderline abstract_t">Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J 2020; 55.</a></li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 2005; 115:34.</a></li><li><a class="nounderline abstract_t">Källén B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999; 93:392.</a></li><li><a class="nounderline abstract_t">Ericson, A, Kallen, B. Use of drugs during pregnancy—unique Swedish registration method can be improved. Information from the Swedish Medical Products Agency 1999; 1:9.</a></li><li><a class="nounderline abstract_t">Cossette B, Beauchesne MF, Forget A, et al. Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy. Ann Allergy Asthma Immunol 2014; 112:459.</a></li><li><a class="nounderline abstract_t">Charlton RA, Snowball JM, Nightingale AL, Davis KJ. Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study. J Allergy Clin Immunol Pract 2015; 3:772.</a></li><li><a class="nounderline abstract_t">Cossette B, Forget A, Beauchesne MF, et al. Impact of maternal use of asthma-controller therapy on perinatal outcomes. Thorax 2013; 68:724.</a></li><li><a class="nounderline abstract_t">Tata LJ, Lewis SA, McKeever TM, et al. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. Thorax 2008; 63:981.</a></li><li><a class="nounderline abstract_t">Dombrowski MP, Schatz M, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol 2008; 111:457. Reaffirmed 2019.</a></li><li><a class="nounderline abstract_t">Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jick SS. Asthma drugs and the risk of congenital anomalies. Pharmacotherapy 2013; 33:363.</a></li><li><a class="nounderline abstract_t">Bain E, Pierides KL, Clifton VL, et al. Interventions for managing asthma in pregnancy. Cochrane Database Syst Rev 2014; :CD010660.</a></li><li><a class="nounderline abstract_t">Namazy JA, Chambers C, Schatz M. Safety of therapeutic options for treating asthma in pregnancy. Expert Opin Drug Saf 2014; 13:1613.</a></li><li><a class="nounderline abstract_t">Murphy VE, Gibson PG. Asthma in pregnancy. Clin Chest Med 2011; 32:93.</a></li><li><a class="nounderline abstract_t">Garne E, Vinkel Hansen A, Morris J, et al. Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy - a cohort linkage study. BJOG 2016; 123:1609.</a></li><li><a class="nounderline abstract_t">Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 2004; 113:1040.</a></li><li><a class="nounderline abstract_t">Bracken MB, Triche EW, Belanger K, et al. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol 2003; 102:739.</a></li><li><a class="nounderline abstract_t">Lim A, Stewart K, König K, George J. Systematic review of the safety of regular preventive asthma medications during pregnancy. Ann Pharmacother 2011; 45:931.</a></li><li><a class="nounderline abstract_t">Schatz M, Zeiger RS, Harden KM, et al. The safety of inhaled beta-agonist bronchodilators during pregnancy. J Allergy Clin Immunol 1988; 82:686.</a></li><li><a class="nounderline abstract_t">Lin S, Munsie JP, Herdt-Losavio ML, et al. Maternal asthma medication use and the risk of gastroschisis. Am J Epidemiol 2008; 168:73.</a></li><li><a class="nounderline abstract_t">Garne E, Hansen AV, Morris J, et al. Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study. J Allergy Clin Immunol 2015; 136:1496.</a></li><li><a class="nounderline abstract_t">Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol 2007; 63:383.</a></li><li><a class="nounderline abstract_t">Gidaya NB, Lee BK, Burstyn I, et al. In utero Exposure to β-2-Adrenergic Receptor Agonist Drugs and Risk for Autism Spectrum Disorders. Pediatrics 2016; 137:e20151316.</a></li><li><a class="nounderline abstract_t">Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J Allergy Clin Immunol 2008; 121:1379.</a></li><li class="breakAll">http://www.reprotox.org/Members/AgentDetail.aspx?a=3721 (Accessed on May 06, 2011).</li><li class="breakAll">http://www.reprotox.org/Members/AgentDetail.aspx?a=4360 (Accessed on May 06, 2011).</li><li><a class="nounderline abstract_t">Wilton LV, Shakir SA. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. Drug Saf 2002; 25:213.</a></li><li><a class="nounderline abstract_t">Eltonsy S, Forget A, Beauchesne MF, Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol 2015; 135:123.</a></li><li><a class="nounderline abstract_t">Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol 2001; 25:145.</a></li><li><a class="nounderline abstract_t">Bakhireva LN, Jones KL, Schatz M, et al. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 2005; 116:503.</a></li><li><a class="nounderline abstract_t">Fitzsimons R, Greenberger PA, Patterson R. Outcome of pregnancy in women requiring corticosteroids for severe asthma. J Allergy Clin Immunol 1986; 78:349.</a></li><li><a class="nounderline abstract_t">Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975; 233:804.</a></li><li><a class="nounderline abstract_t">Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.</a></li><li><a class="nounderline abstract_t">Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93.</a></li><li><a class="nounderline abstract_t">Perlow JH, Montgomery D, Morgan MA, et al. Severity of asthma and perinatal outcome. Am J Obstet Gynecol 1992; 167:963.</a></li><li><a class="nounderline abstract_t">Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202:436.</a></li><li><a class="nounderline abstract_t">Namazy JA, Murphy VE, Powell H, et al. Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes. Eur Respir J 2013; 41:1082.</a></li><li><a class="nounderline abstract_t">Stenius-Aarniala B, Piirilä P, Teramo K. Asthma and pregnancy: a prospective study of 198 pregnancies. Thorax 1988; 43:12.</a></li><li><a class="nounderline abstract_t">Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005; 330:230.</a></li><li class="breakAll">Schatz, M, Hoffman, et al. Asthma and allergic diseases during pregnancy. In: Middleton's Allergy: Principles and Practice, 6th, Adkinson, NF, Yunginger, JW, Busse, WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1303.</li><li><a class="nounderline abstract_t">Namazy J, Schatz M, Long L, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004; 113:427.</a></li><li><a class="nounderline abstract_t">Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003; 111:736.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Patterson R. Beclomethasone diproprionate for severe asthma during pregnancy. Ann Intern Med 1983; 98:478.</a></li><li><a class="nounderline abstract_t">Dombrowski MP, Brown CL, Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. J Matern Fetal Med 1996; 5:310.</a></li><li><a class="nounderline abstract_t">Dombrowski MP, Schatz M, Wise R, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol 2004; 190:737.</a></li><li><a class="nounderline abstract_t">Dombrowski M, Thom E, McNellis D. Maternal-Fetal Medicine Units (MFMU) studies of inhaled corticosteroids during pregnancy. J Allergy Clin Immunol 1999; 103:S356.</a></li><li><a class="nounderline abstract_t">Blais L, Beauchesne MF, Rey E, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007; 62:320.</a></li><li><a class="nounderline abstract_t">Blais L, Beauchesne MF, Lemière C, Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 2009; 124:1229.</a></li><li><a class="nounderline abstract_t">Breton MC, Beauchesne MF, Lemière C, et al. Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy. J Allergy Clin Immunol 2010; 126:772.</a></li><li><a class="nounderline abstract_t">Hodyl NA, Stark MJ, Osei-Kumah A, et al. Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroid use for asthma during pregnancy. Am J Respir Crit Care Med 2011; 183:716.</a></li><li><a class="nounderline abstract_t">Tegethoff M, Greene N, Olsen J, et al. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study. Am J Respir Crit Care Med 2012; 185:557.</a></li><li><a class="nounderline abstract_t">Wendel PJ, Ramin SM, Barnett-Hamm C, et al. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol 1996; 175:150.</a></li><li class="breakAll">National Asthma Education and Prevention Program Expert Panel Executive Summary Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. National Institutes of Health, National Heart, Lung, and Blood Institute, Publication No. 02-5075, 2002. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (Accessed on March 1, 2006).</li><li><a class="nounderline abstract_t">Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007; 119:618.</a></li><li><a class="nounderline abstract_t">Sarkar M, Koren G, Kalra S, et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009; 65:1259.</a></li><li><a class="nounderline abstract_t">Nelsen LM, Shields KE, Cunningham ML, et al. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. J Allergy Clin Immunol 2012; 129:251.</a></li><li class="breakAll">Reprotox. http://www.reprotox.org/Members/AgentDetail.aspx?a=4087 (Accessed on May 06, 2011).</li><li class="breakAll">Reprotox. http://www.reprotox.org/Members/AgentDetail.aspx?a=3993 (Accessed on May 06, 2011).</li><li class="breakAll">Reprotox. http://www.reprotox.org/Members/AgentDetail.aspx?a=3722 (Accessed on May 06, 2011).</li><li><a class="nounderline abstract_t">Bucher HU, Gautschi K. [Detection of caffeine, theophylline and theobromine in the umbilical cord blood and breast milk]. Helv Paediatr Acta 1985; 40:163.</a></li><li><a class="nounderline abstract_t">Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020; 145:528.</a></li><li class="breakAll">US Food and Drug Administration. Reslizumab (Cinqair) prescribing information http://www.cinqair.com/pdf/PrescribingInformation.pdf (Accessed on September 01, 2016).</li><li class="breakAll">US Food and Drug Administration. Mepolizumab prescribing information. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF (Accessed on September 01, 2016).</li><li class="breakAll">US Food and Drug Administration. Prescribing information for Fasenra (benralizumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf (Accessed on May 07, 2018).</li><li><a class="nounderline abstract_t">Manetz S, Maric I, Brown T, et al. Successful pregnancy in the setting of eosinophil depletion by benralizumab. J Allergy Clin Immunol Pract 2021; 9:1405.</a></li><li><a class="nounderline abstract_t">Mepolizumab (Nucala) for severe eosinophilic asthma. Med Lett Drugs Ther 2016; 58:11.</a></li><li><a class="nounderline abstract_t">Ozden G, Pınar Deniz P. May mepolizumab used in asthma correct subfertility? Ann Med 2021; 53:456.</a></li><li class="breakAll">US Food and Drug Administration. Prescribing information for Dupixent (dupilumab). https://www.regeneron.com/downloads/dupixent_fpi.pdf (Accessed on August 26, 2022).</li><li><a class="nounderline abstract_t">Shakuntulla F, Chiarella SE. Safety of Biologics for Atopic Diseases During Pregnancy. J Allergy Clin Immunol Pract 2022; 10:3149.</a></li><li class="breakAll">US Food and Drug Administration. Prescribing information for Tezspire (tezepelumab). https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e306dc06-d580-4457-b15f-9f28545ad63a/e306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf (Accessed on August 28, 2022).</li><li><a class="nounderline abstract_t">Labovitz E, Spector S. Placental theophylline transfer in pregnant asthmatics. JAMA 1982; 247:786.</a></li><li><a class="nounderline abstract_t">Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol 2020; 146:1217.</a></li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Schatz M, Dombrowski MP, Wise R, et al. Spirometry is related to perinatal outcomes in pregnant women with asthma. Am J Obstet Gynecol 2006; 194:120.</a></li><li><a class="nounderline abstract_t">Newman RB, Momirova V, Dombrowski MP, et al. The effect of active and passive household cigarette smoke exposure on pregnant women with asthma. Chest 2010; 137:601.</a></li><li><a class="nounderline abstract_t">Murphy VE, Clifton VL, Gibson PG. The effect of cigarette smoking on asthma control during exacerbations in pregnant women. Thorax 2010; 65:739.</a></li><li><a class="nounderline abstract_t">Baarnes CB, Hansen AV, Ulrik CS. Enrolment in an Asthma Management Program during Pregnancy and Adherence with Inhaled Corticosteroids: The 'Management of Asthma during Pregnancy' Program. Respiration 2016; 92:9.</a></li><li><a class="nounderline abstract_t">Schatz M, Zeiger RS, Hoffman CP. Intrauterine growth is related to gestational pulmonary function in pregnant asthmatic women. Kaiser-Permanente Asthma and Pregnancy Study Group. Chest 1990; 98:389.</a></li><li><a class="nounderline abstract_t">Powell H, Murphy VE, Taylor DR, et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378:983.</a></li><li><a class="nounderline abstract_t">Ali Z, Hansen AV, Ulrik CS. Exacerbations of asthma during pregnancy: Impact on pregnancy complications and outcome. J Obstet Gynaecol 2016; 36:455.</a></li><li><a class="nounderline abstract_t">Grzeskowiak LE, Smith B, Roy A, et al. Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study. ERJ Open Res 2016; 2.</a></li><li><a class="nounderline abstract_t">Cydulka RK. Acute asthma during pregnancy. Immunol Allergy Clin North Am 2006; 26:103.</a></li><li><a class="nounderline abstract_t">Bonham CA, Patterson KC, Strek ME. Asthma Outcomes and Management During Pregnancy. Chest 2018; 153:515.</a></li><li class="breakAll">Bristish Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: A national clinical guideline. May 2008; revised January 2012. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-guideline-on-the-management-of-asthma/ (Accessed on June 10, 2016).</li><li class="breakAll">Schatz, M, Wise, RA. Acute asthma in pregnancy. In: Acute Asthma: Assessment and Management, Corbridge T, et al (Eds), McGraw-Hill, New York 2000.</li><li><a class="nounderline abstract_t">Wolsk HM, Chawes BL, Litonjua AA, et al. Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials. PLoS One 2017; 12:e0186657.</a></li><li><a class="nounderline abstract_t">Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? J Allergy Clin Immunol 2007; 120:1031.</a></li><li><a class="nounderline abstract_t">Litonjua AA, Carey VJ, Laranjo N, et al. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. JAMA 2016; 315:362.</a></li><li><a class="nounderline abstract_t">Chawes BL, Bønnelykke K, Stokholm J, et al. Effect of Vitamin D3 Supplementation During Pregnancy on Risk of Persistent Wheeze in the Offspring: A Randomized Clinical Trial. JAMA 2016; 315:353.</a></li><li><a class="nounderline abstract_t">Brustad N, Eliasen AU, Stokholm J, et al. High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. JAMA 2019; 321:1003.</a></li><li><a class="nounderline abstract_t">Litonjua AA, Carey VJ, Laranjo N, et al. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. N Engl J Med 2020; 382:525.</a></li><li><a class="nounderline abstract_t">Bi WG, Nuyt AM, Weiler H, et al. Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis. JAMA Pediatr 2018; 172:635.</a></li><li><a class="nounderline abstract_t">Minerbi-Codish I, Fraser D, Avnun L, et al. Influence of asthma in pregnancy on labor and the newborn. Respiration 1998; 65:130.</a></li><li><a class="nounderline abstract_t">Arakawa H, Lötvall J, Kawikova I, et al. Leukotriene D4- and prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: role of thromboxane and its receptor. Br J Pharmacol 1993; 110:127.</a></li><li><a class="nounderline abstract_t">Kawikova I, Barnes PJ, Takahashi T, et al. 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am J Respir Crit Care Med 1996; 153:590.</a></li><li class="breakAll">American College of Obstetrics and Gynecology. Obstetric Hemorrhage Checklist. https://www.acog.org/-/media/Districts/District-II/Public/SMI/v2/sm07a170130StagesHemorrCheck.pdf?dmc=1&amp;ts=20170517T1806387225 (Accessed on November 09, 2017).</li><li><a class="nounderline abstract_t">Towers CV, Briggs GG, Rojas JA. The use of prostaglandin E2 in pregnant patients with asthma. Am J Obstet Gynecol 2004; 190:1777.</a></li></ol></div><div id="topicVersionRevision">Topic 554 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821270" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26408052" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Maternal asthma medication use during pregnancy and risk of congenital heart defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27012010" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Treatment of Allergic Respiratory Disease During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845267" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Asthma during pregnancy--a population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845267" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Asthma during pregnancy--a population based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443143" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The effect of pregnancy on the course of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208460" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Update in the treatment of asthma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643278" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Asthma Is Associated With Pregnancy Loss and Recurrent Pregnancy Loss: A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643278" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Asthma Is Associated With Pregnancy Loss and Recurrent Pregnancy Loss: A Nationwide Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699837" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31699837" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637545" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074986" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Congenital malformations after the use of inhaled budesonide in early pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Use of drugs during pregnancy—unique Swedish registration method can be improved</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656659" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26116951" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23585516" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of maternal use of asthma-controller therapy on perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678701" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18238988" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450814" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Asthma drugs and the risk of congenital anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25331331" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interventions for managing asthma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25382594" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety of therapeutic options for treating asthma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21277452" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Asthma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27172856" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy - a cohort linkage study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208581" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The relationship of asthma medication use to perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14551004" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21712513" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systematic review of the safety of regular preventive asthma medications during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3171009" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The safety of inhaled beta-agonist bronchodilators during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436535" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Maternal asthma medication use and the risk of gastroschisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26220526" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17279357" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26738885" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In utero Exposure toβ-2-Adrenergic Receptor Agonist Drugs and Risk for Autism Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410961" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410961" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410961" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11945116" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25226849" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk of congenital malformations for asthmatic pregnant women using a long-actingβ₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453610" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The efficacy and safety of asthma medications during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159616" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Asthma medication use in pregnancy and fetal growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3734287" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Outcome of pregnancy in women requiring corticosteroids for severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1173879" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Corticosteroid therapy for the pregnant asthmatic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11091360" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15013068" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1415433" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Severity of asthma and perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/705336" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prenatal exposure to prednisone in humans and animals retards intrauterine growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903964" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2895502" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Asthma and pregnancy: a prospective study of 198 pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659480" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659480" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007341" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704351" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6838070" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Beclomethasone diproprionate for severe asthma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8972405" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Preliminary experience with triamcinolone acetonide during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042007" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9949338" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Maternal-Fetal Medicine Units (MFMU) studies of inhaled corticosteroids during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17121872" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910032" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20920768" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20935111" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroid use for asthma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198975" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694041" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Asthma treatment in pregnancy: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694041" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Asthma treatment in pregnancy: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17336611" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety of leukotriene receptor antagonists in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707749" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000568" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000568" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000568" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22000568" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3855177" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : [Detection of caffeine, theophylline and theobromine in the umbilical cord blood and breast milk].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145939" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145939" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145939" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145939" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33316460" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful pregnancy in the setting of eosinophil depletion by benralizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26761344" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mepolizumab (Nucala) for severe eosinophilic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33739210" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : May mepolizumab used in asthma correct subfertility?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33739210" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : May mepolizumab used in asthma correct subfertility?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35987486" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety of Biologics for Atopic Diseases During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35987486" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Safety of Biologics for Atopic Diseases During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7057554" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Placental theophylline transfer in pregnant asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389020" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Spirometry is related to perinatal outcomes in pregnant women with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820079" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The effect of active and passive household cigarette smoke exposure on pregnant women with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20627905" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The effect of cigarette smoking on asthma control during exacerbations in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27348313" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Enrolment in an Asthma Management Program during Pregnancy and Adherence with Inhaled Corticosteroids: The 'Management of Asthma during Pregnancy' Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2376171" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Intrauterine growth is related to gestational pulmonary function in pregnant asthmatic women. Kaiser-Permanente Asthma and Pregnancy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21907861" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26467747" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Exacerbations of asthma during pregnancy: Impact on pregnancy complications and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27730170" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16443146" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Acute asthma during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28867295" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Asthma Outcomes and Management During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28867295" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Asthma Outcomes and Management During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28867295" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Asthma Outcomes and Management During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29077711" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919705" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Is vitamin D deficiency to blame for the asthma epidemic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26813209" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26813208" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effect of Vitamin D3 Supplementation During Pregnancy on Risk of Persistent Wheeze in the Offspring: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30860552" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32023372" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29813153" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580925" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Influence of asthma in pregnancy on labor and the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8220872" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Leukotriene D4- and prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: role of thromboxane and its receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8564103" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8564103" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284797" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The use of prostaglandin E2 in pregnant patients with asthma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
